Fig. 2From: Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective studyOS of the patients with EGFR 19del or L858R between the two groups. a EGFR 19del. b L858RBack to article page